Triton to weigh takeover deal for drug developer Evotec

Triton Partners is considering a takeover bid for Germany's Evotec SE after the private equity firm became one of the drug developer's largest shareholders, according to people familiar with the matter.

Triton is among several investment firms that have explored a deal for Evotec in recent months, the people said, asking not to be identified because the information is private. Any takeover of Evotec by a private equity firm could be complicated by the fact that the company is expected to report negative free cash flow this year and next, the people said.